Jump to content

Idalopirdine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Boghog (talk | contribs) at 05:45, 24 April 2022 (templated cites). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Idalopirdine
Clinical data
Other namesLu-AE-58054
ATC code
  • None
Identifiers
  • 2-(6-Fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.245.270 Edit this at Wikidata
Chemical and physical data
FormulaC20H19F5N2O
Molar mass398.377 g·mol−1
3D model (JSmol)
  • FC(F)C(F)(F)COc1cccc(c1)CNCCc3c[nH]c2cc(F)ccc23
  • InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2 ☒N
  • Key:YBAWYTYNMZWMMJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of October 2013 it is in phase III clinical trials.[2]

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.[3] Two further phase III trials failed too, the company confirmed in early 2017.[3]

See also

References

  1. ^ "U.S. Development Programs". Lundbeck.
  2. ^ a b "Search of: Lu AE58054 - List Results". ClinicalTrials.gov. National Library of Medicine, U.S. Department of Health and Human Services.
  3. ^ a b Taylor NP (23 September 2016). "PhIII Alzheimer's flop takes chunk out of Lundbeck, hits Axovant with aftershocks".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Idalopirdine&oldid=1084389766"